Type 2 biomarkers that predict both likelihood of future severe exacerbations and response to monoclonal antibody therapy in asthma, would be useful clinically in identifying patients both at greater risk of hospitalization, and most likely to benefit from monoclonal antibody therapy.
To describe the association between the Type 2 biomarkers, blood eosinophils, FeNO, serum periostin, serum IgE and time to severe exacerbation in a broad asthma population.
Participants from two adult asthma cohorts with baseline measurements of blood eosinophils, FeNO, serum periostin and serum IgE were reviewed after at least 12 months to obtain an exacerbation history, corroborated with general practitioner and hospital medical records. The association between baseline Type 2 biomarkers and time to exacerbation was described by Cox Proportional Hazard Ratios (HR) using multivariate models.
212 participants were followed for a median (range) 3.8 (1.1 to 5.3) years. 67/212 (32%) had at least one severe exacerbation. The HR (95% CI) of baseline Type 2 biomarkers and time to exacerbation were: blood eosinophils per 0.1x109/L increase 0.89 (0.76-1.05), P=0.17; log FeNO per 0.693 increase 0.65 (0.52-0.81), P<0.001; log serum periostin per 0.693 increase 0.62 (0.35-1.09), P=0.10; log serum IgE per 0.693 increase 0.89 (0.80-1.00), P=0.05.
The positive association between Type 2 biomarkers and risk of severe exacerbations in populations with severe refractory asthma does not extend to mild and moderate asthma. Non-Type 2 asthma may represent a phenotype associated with an increased risk of severe exacerbations in a broad asthma population.
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 January 2022.
All research outputs
#3,052,573
of 28,153,575 outputs
Outputs from The Journal of Allergy and Clinical Immunology: In Practice
#901
of 4,645 outputs
Outputs of similar age
#55,418
of 348,182 outputs
Outputs of similar age from The Journal of Allergy and Clinical Immunology: In Practice
#20
of 95 outputs
Altmetric has tracked 28,153,575 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,645 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 348,182 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.
